Downregulation of PAX1 in OSCC Enhances Stemness and Immunosuppression via IFIT1 and PD ‐ L1 Pathways
Oral Diseases · 2025
DOI: 10.1111/odi.15225 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oral Diseases, 2025. Verfasst von Hui-Hsin Ko und 11 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Institute of Clinical Dentistry, School of Dentistry, National Taiwan University, Taipei, Taiwan. Hauptthemen laut MEDLINE: B7-H1 Antigen, Mouth Neoplasms, Neoplastic Stem Cells, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Ministry of Science and Technology, Taipei, Taiwan.
Abstract (Originalsprache)
Objective
Our study investigated how arecoline‐induced extracellular vesicle (EV) secretion suppresses PAX1 protein production through DNA hypermethylation and examined whether PAX1 downregulation enhances cancer stemness and immunosuppression in the tumor microenvironment. Materials and Methods EVs were isolated from SAS/TW2.6 cancer cell lines using ultracentrifugation and identified using transmission electron microscopy. PAX1 DNA methylation was tested in an ISO17025‐certified lab, with and without EV pretreatment. Stemness and epithelial–mesenchymal transition markers were assessed by western blotting and 3D culture. PAX1, IFIT1, and PD‐L1 co‐expression were examined through immunofluorescence. Flow cytometry detected various T cells.
Results
Arecoline‐induced EVs enhanced PAX1 methylation, suppressing its tumor‐suppressive function. Reduced PAX1 mRNA in OSCCs was linked to larger tumors, nodal metastasis, late‐stage disease, areca quid chewing, and poor survival. Downregulated PAX1 protein negatively correlated with IFIT1 and PD‐L1 expression. Reduced PAX1 promoted stemness via the IFIT1 pathway, increasing PD‐L1 secretion and aiding immune evasion. PD‐L1 expression correlated with Treg and CD8+ T cell levels in OSCC tissues, and the CD4+/CD8+ T cell ratio was lower in OSCC patients than in controls.
Conclusion
Arecoline‐induced EV production, which influences PAX1/IFIT1/PD‐L1 function, may serve as a reliable biomarker for targeted therapy in OSCC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate Institute of Clinical Dentistry, School of Dentistry, National Taiwan University, Taipei, Taiwan.
- School of Dentistry, National Taiwan University, Taipei, Taiwan.
- Department of Dentistry, College of Medicine, National Taiwan University Hospital, Taipei, Taiwan.
- Department of Dentistry, National Taiwan University Hospital Hsin-Chu Branch, Hsin-Chu, Taiwan.
- Graduate Institute of Oral Biology, School of Dentistry, National Taiwan University, Taipei, Taiwan.
- National Institute of Cancer Research, National Health Research Institutes, Zhunan, Taiwan.
ORCID-Profile: Shih-Jung Cheng
Förderung
- Ministry of Science and Technology, Taipei, Taiwan
Zitieren
APA
Ko, H. H., Peng, H. H., Chou, H. E., Hou, H. H., Liu, W. W., Kuo, M. Y., Lee, A. Y., Kao, H. F., Lin, H. Y., Chang, Y. C., Kuo, W. T., & Cheng, S. J. (2025). Downregulation of PAX1 in OSCC Enhances Stemness and Immunosuppression via IFIT1 and PD ‐ L1 Pathways. Oral Diseases. https://doi.org/10.1111/odi.15225
Vancouver
Ko HH, Peng HH, Chou HE, Hou HH, Liu WW, Kuo MY, et al. Downregulation of PAX1 in OSCC Enhances Stemness and Immunosuppression via IFIT1 and PD ‐ L1 Pathways. Oral Diseases. 2025. doi:10.1111/odi.15225
BibTeX
@article{Ko2025,
author = {Ko, Hui-Hsin and Peng, Hsin-Hui and Chou, Han-Yi E and Hou, Hsin-Han and Liu, Wei-Wen and Kuo, Mark Yen-Ping and Lee, Alan Yueh-Luen and Kao, Hsiang-Fong and Lin, Hung-Ying and Chang, Ying-Chieh and Kuo, Wei-Ting and Cheng, Shih-Jung},
title = {Downregulation of PAX1 in OSCC Enhances Stemness and Immunosuppression via IFIT1 and PD ‐ L1 Pathways},
journal = {Oral Diseases},
year = {2025},
doi = {10.1111/odi.15225}
}
EUVIMED